Reported 2 days ago
Pfizer Inc. (NYSE:PFE) has received FDA approval for its supplemental Biologics License Application (sBLA) concerning the LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1), which is intended for adults 65 and older and younger individuals aged 5 to 64 with high-risk underlying conditions. The approval is based on extensive evidence showcasing the vaccine's safety and efficacy, including data from clinical trials for children aged 5 to 11.
Source: YAHOO